comparemela.com
Latest Breaking News On - Uc health anita afzali - Page 1 : comparemela.com
Guselkumab Demonstrates Long-Term Benefit for Crohn Disease
During the long-term extension of the GALAXI trial, 54.1% of participants treated with guselkumab achieved clinical remission and 34.7% achieved endoscopic response.
Jan-wehkamp
Anita-afzali
Uc-health-anita-afzali
Johnson
University-of-cincinnati-college-medicine
Johnson-innovative-medicines
United-european-gastroenterology-week
Cincinnati-college
Johnson-innovative
Severely-active-crohn
Participants-with-moderately
Achieved-clinical-remission
vimarsana © 2020. All Rights Reserved.